Allergan Moves Into Busy CGRP Class By Buying Merck’s Oral Drugs
This article was originally published in The Pink Sheet Daily
Allergan agreed to pay $250 million up front for global rights two investigational oral CGRP antagonists in early clinical development for acute treatment and prevention of migraine. Several rivals are racing to develop injectable CGRP antibodies.
You may also be interested in...
Biopharma financing totaled $9.7 billion, almost half from follow-on public offerings; there was big consolidation in the generics and health services industries. AstraZeneca signed a dozen partnerships, many of which focused on oncology.
Allergan announced a licensing deal with Mimetogen to commercialize a TrkA agonist for the treatment of dry eye disease, coinciding with its third quarter earnings call and R&D day, but avoided discussion of the elephant in the room.
The U.S. market share for Sandoz/Momenta’s generic version of Copaxone is under 5% of the total glatiramer market, Teva said during its second quarter sales and earnings call.